Overexpression of a splice variant of oncostatin M receptor beta in XXXX @entity1721 .

@entity1 @entity3145 @entity5 @entity9255 @entity1721 @entity7168 @entity1778 @entity18037
BACKGROUND: Expression of oncostatin M receptor beta ( @entity18037 ) has been reported in @entity1 @entity5 , however its role in @entity1721 ( @entity1721 ) remains unknown. Using differential display, earlier we reported the identification of an alternatively spliced variant of @entity18037 in @entity1721 . Here in we characterized this novel variant encoding a soluble form of this receptor (sOSMRb) and determined its clinical significance and correlation with the expression of oncostatin ( @entity9255 ) and @entity1778 inhibitory factor receptor beta ( @entity7168 b) in @entity1721 . MATERIALS AND METHODS: In silico analysis was carried out to characterize the differentially expressed transcript of @entity18037 and its expression was determined in ESCCs and matched normal esophageal tissues using semiquantitative RT-PCR. The expressions of both truncated and full length @entity18037 proteins were analyzed in @entity1721 tissues and @entity1 ' sera using western blotting and immunoprecipitation. By immunoprecipitation we have also shown direct interaction between sOSMRB and @entity9255 . We also explored the relationship between expression of @entity9255 and its receptors, @entity18037 and LIFRb, in primary @entity1 ESCCs and normal epithelia using immunohistochemistry. RESULTS: Overexpression of alternatively spliced @entity18037 b transcript was detected by RT-PCR in 9 of 11 ESCCs. Analysis of the soluble receptor revealed absence of sOSMRb protein in esophageal tissues, however, immunoprecipitation and western blot analysis showed its presence in sera of @entity1721 @entity1 further confirming expression of the alternatively spliced @entity18037 b in @entity1721 @entity1 . Immunohistochemical analysis in @entity3145 ( @entity3145 ) format showed expression of @entity18037 , @entity7168 and @entity9255 in 11/50 (23%), 47/50 (94%) and 47/50 (94%) ESCCs, respectively. Strong correlation was observed between cytoplasmic expression of LIFRb and @entity9255 in @entity5 cells (p = 0.000, O.R = 50, 95%CI = 8-31.9), and nuclear expression of LIFRb and @entity9255 (p = 0.039 OR = 3.1, 95% CI = 1.1-8.2), suggesting that LIFRb serves as the major receptor in ESCCs. CONCLUSION: An alternatively spliced variant of @entity18037 transcribing a soluble form of this receptor has been characterized in @entity1721 . We speculate that the truncated @entity18037 characterized here in may act as a neutralizing receptor for @entity9255 . Our immunohistochemical study showed that @entity18037 and its pathway is not activated in ESCCs.
